Telehealth ADHD Prescribing: What PMHNPs Can Do in Texas

You’re a psychiatrist or PMHNP considering telehealth, and you’re wondering: Can I legally prescribe Adderall or Ritalin through a video visit? It’s a fair question—and one that’s gotten more complicated over the past few years.

The short answer: Yes, psychiatrists can prescribe ADHD medications via telehealth in 2026—but the rules are in flux, and what’s allowed depends on both federal policy and your state’s laws.

Let’s break down what you actually need to know to practice safely and compliantly, without the legal jargon runaround.

The Federal Telehealth Prescribing Landscape: Extended, But Not Permanent

Here’s the reality: ADHD medications like Adderall, Vyvanse, and Ritalin are Schedule II controlled substances. Under normal circumstances, the Ryan Haight Act (2008) requires an in-person medical evaluation before a provider can prescribe any controlled substance via telemedicine.

But COVID changed everything. When the pandemic hit, the DEA waived that in-person requirement, allowing psychiatrists to initiate stimulant prescriptions entirely through telehealth. That flexibility was supposed to be temporary—but it’s been extended multiple times as policymakers debated what comes next.

As of early 2026, those pandemic-era flexibilities have been extended through the end of 2025 (Axios, Nov 2024). This is now the third extension, pushing the decision point into late 2025 or early 2026.

What does that mean practically? Right now, you can start a new ADHD patient on stimulants via telehealth without an in-person visit—as long as you conduct a proper evaluation via live video and meet the standard of care. But if Congress or the DEA doesn’t make this permanent (or create a new pathway), the Ryan Haight in-person requirement could snap back, potentially disrupting virtual ADHD care nationwide.

What Happens If the Waiver Expires?

If the federal flexibility ends without replacement, providers would likely need to see new controlled-substance patients in person at least once before prescribing stimulants via telehealth. Existing patients you started during the waiver period would probably be grandfathered in, but new patient onboarding could require coordination with local clinics for initial exams—or a hybrid model where you see patients in-office initially, then manage them virtually.

The DEA has floated the idea of a ‘special registration’ for telemedicine prescribing of controlled substances, which would allow qualified providers to prescribe stimulants online without in-person visits (RxAgent, 2025). But as of February 2026, no final rule has been implemented. Keep an eye on DEA announcements—this could be the long-term solution.

Bottom line: Telehealth ADHD prescribing is legal and operational right now, but you should have a contingency plan in case federal rules tighten in 2026.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-Specific Rules: Where You Can (and Can’t) Prescribe Stimulants Online

Federal law sets the baseline, but state laws add another layer—and they vary wildly, especially if you’re a PMHNP rather than an MD.

Psychiatrists (MD/DO): Full Authority Everywhere

If you’re a psychiatrist, you have unrestricted prescribing authority in every state (assuming you’re licensed there). You can prescribe Schedule II stimulants via telehealth as long as:

• You comply with federal telehealth rules (extended through 2025)
• You conduct a proper evaluation via live video
• You check your state’s Prescription Drug Monitoring Program (PDMP) before prescribing
• You follow standard-of-care practices (thorough assessment, informed consent, appropriate follow-up)

Some states have additional telehealth-specific requirements—like Florida, which explicitly allows telehealth prescribing of Schedule II stimulants for psychiatric disorders (Florida Statute 456.47)—but none outright ban psychiatrists from prescribing ADHD meds online if federal law permits it.

PMHNPs: Your State Determines What You Can Do

If you’re a PMHNP, your prescribing authority depends entirely on where you’re licensed. Some states treat you nearly equal to a psychiatrist; others severely restrict what you can prescribe—even with a collaborating physician.

States Where PMHNPs Can Prescribe ADHD Meds Independently (After Experience):

• New York: After 3,600 hours of supervised practice (~2 years), PMHNPs can practice and prescribe independently, including Schedule II stimulants (RxAgent, 2025).
• Illinois: After 4,000 hours of practice plus additional training, PMHNPs can obtain Full Practice Authority and prescribe ADHD meds without a collaborating physician (RxAgent, 2025).
• California: Experienced PMHNPs (≥3 years/4,600 hours) can apply for independent practice status (‘104 NP’) as of 2023 and prescribe stimulants autonomously—though they must complete a controlled-substance pharmacology course first (RxAgent, 2025).

States Where PMHNPs Need Physician Collaboration (With Restrictions):

• Texas: PMHNPs cannot prescribe Schedule II stimulants to outpatient ADHD patients at all—only MDs can. NPs are limited to hospital, hospice, or emergency settings for Schedule II prescriptions (RxAgent, 2025). If you’re a PMHNP in Texas, you’ll need a psychiatrist to write stimulant prescriptions while you handle therapy or non-stimulant meds.

• Florida: PMHNPs must work under a psychiatrist’s protocol and are normally limited to 7-day supplies of Schedule II drugs—except Florida carved out an exception for ‘psychiatric nurses’ treating mental health conditions, who can prescribe 30-day supplies under a psychiatrist’s supervision (Florida Statute 464.012). So you can manage ADHD meds in Florida as a PMHNP—but you can’t do it solo.

• Pennsylvania: PMHNPs can prescribe Schedule II meds, but only 72 hours’ worth for a new patient/condition, and must notify their collaborating physician. Ongoing refills are limited to 30 days (RxAgent, 2025). It’s workable, but requires tight coordination with your supervising MD.

The takeaway: If you’re a PMHNP, verify your state’s scope-of-practice laws before launching a telehealth ADHD practice. In states like Texas, you’ll need an MD partner to prescribe stimulants at all. In states like New York or Illinois, you can operate independently once you meet experience thresholds.

What Does a Compliant Telehealth ADHD Visit Actually Look Like?

Federal and state regulators have made clear: telehealth doesn’t mean shortcuts. If you’re prescribing stimulants via video, you need to meet the same standard of care you would in-office. Here’s what that looks like in practice:

Initial Evaluation (New ADHD Patients)

• Comprehensive psychiatric assessment: Full clinical interview, DSM-5 symptom criteria for ADHD, ruling out other conditions (anxiety, bipolar, substance use). Use standardized rating scales like the ASRS (adults) or Conners/Vanderbilt (pediatric) to support diagnosis.
• Collateral information: For kids/teens, get input from parents and teachers. For adults, consider partner or work performance data if relevant.
• Medical history and risk assessment: Document cardiovascular history, family history of sudden death or arrhythmia, current meds, substance use. While you don’t need a physical exam to diagnose ADHD, many psychiatrists ask patients to check their blood pressure/heart rate (home cuff or pharmacy visit) before starting stimulants.
• Informed consent: Discuss risks (cardiovascular, abuse potential, side effects), benefits, alternatives (behavioral therapy, non-stimulants), and monitoring plan.
• PDMP check: Query your state’s Prescription Drug Monitoring Program to check for overlapping controlled-substance prescriptions or red flags.

Follow-Up Visits (Ongoing Medication Management)

ADHD medication management typically involves monthly visits, since stimulants are dispensed in 30-day supplies with no refills (Schedule II rule). These can be brief (15-20 minutes):

• Symptom monitoring (ADHD symptom improvement, functional gains at work/school)
• Side-effect check (appetite, sleep, mood, heart rate/BP)
• Adherence and any signs of misuse
• Dose adjustments if needed
• Periodic PDMP re-checks (many states require checking at least every 90 days for controlled substances)

Documentation Best Practices

Given the scrutiny on telehealth ADHD prescribing (after high-profile cases of platforms over-prescribing stimulants with minimal oversight—Texas SB 2527 analysis, 2023), you want airtight documentation:

• Note patient location each visit (state where they’re physically located—matters for licensure)
• Document consent for telehealth (required by many states)
• Justify diagnosis with specific symptoms and functional impairment
• Record vital signs if you’ve asked patient to self-report
• Note your PDMP check and any findings
• Document clinical reasoning for dose changes or med switches

E-Prescribing: Most states now require controlled substances to be e-prescribed (Texas, California, New York, Illinois, Pennsylvania all mandate it). Make sure your telehealth platform uses a DEA-compliant e-prescribing system with two-factor authentication.

Reimbursement: Are You Actually Getting Paid for Telehealth ADHD Visits?

Here’s the good news: Telehealth reimbursement for psychiatric medication management is now on par with in-person visits in nearly every state.

As of 2026, 48 states have enacted some form of telehealth payment parity for mental health services (BehaveHealth, 2024). This means Medicare, Medicaid, and most private insurers pay the same rate for a virtual med check as they would for an office visit.

What Psychiatrists Typically Earn Per Visit

For medication management, you’ll usually bill E/M codes:

• 99213 (15-min established patient visit): Medicare pays ~$89-95; private insurance often $100-130 (Therathink, 2026)
• 99214 (25-min visit, moderate complexity): Medicare ~$125-136; private often $140-170
• 90792 (Initial psychiatric evaluation with med services): Medicare ~$188-202 (Therathink, 2026)

Medicaid rates are lower—often around $40-65 for a med check depending on the state (Therathink, 2026)—but the volume is there if you want to serve that population.

Psychiatrists vs Other Providers: Who Gets Paid More?

Psychiatrists (MD/DO) are reimbursed at the highest levels for medication management services (Therathink, 2026). PMHNPs billing under their own NPI typically get paid at 85% of the physician rate by Medicare (though some private plans pay NPs at full parity). This is one reason platforms often credential psychiatrists—they maximize reimbursement and can handle any prescribing scenario without scope-of-practice restrictions.

The Telehealth Efficiency Advantage

Here’s where telehealth shines: no office overhead. You’re not paying rent, utilities, or front-desk staff. A psychiatrist doing four 15-minute telehealth med checks per hour (with good scheduling) could gross $400-500+/hour from private insurance—and that’s working from your home office.

Compare that to a traditional brick-and-mortar practice where you’re spending 30-40% of revenue on overhead, plus commute time. Telehealth ADHD medication management is one of the most financially efficient models in psychiatry right now.

The Patient Demand Side: Why ADHD Telehealth Took Off (and Hasn’t Slowed Down)

ADHD prescriptions surged during the pandemic—stimulant prescriptions jumped significantly in 2020-2022, especially among adults (Associated Press, Jan 2024). Why? Telehealth made it easier for adults (especially those who’d struggled undiagnosed for years) to seek help. Instead of waiting months for a psychiatry appointment and taking time off work, patients could see a provider via video in weeks—or even days.

That demand hasn’t gone away. Waitlists for in-person psychiatrists remain long (often 2-6 months in many states), and patients value the convenience of virtual visits—no commute, no waiting room, easier to fit into a lunch break.

The Flip Side: Medication Shortages and Scrutiny

The surge in ADHD diagnoses also contributed to nationwide stimulant shortages starting in late 2022. Adderall, Vyvanse, and other stimulants have been periodically backordered, frustrating both patients and providers (Axios, 2024). The DEA even had to raise manufacturing quotas to address the shortage (Axios, Sept 2024).

As a provider, this means you’ll sometimes have to work with patients to find pharmacies that have their medication in stock, or switch to alternative formulations or non-stimulants (atomoxetine, bupropion, viloxazine) when first-line options aren’t available.

There’s also been increased regulatory scrutiny of telehealth ADHD prescribing. Some online platforms were found to be inappropriately prescribing stimulants after minimal evaluations—essentially ‘pill mills’ for Adderall (Texas Legislature, 2023). This has put all telehealth ADHD providers under a microscope.

The way to stay on the right side of that line: thorough evaluations, clear documentation, appropriate follow-up, and no shortcuts. If you’re doing real psychiatry—not just rubber-stamping prescriptions—you’re fine. But it’s a reminder that quality matters, especially in a space regulators are watching closely.

State-by-State Snapshot: Where You Can Practice (and What to Watch Out For)

Here’s a quick rundown of key considerations in the six priority states for telehealth ADHD prescribing:

California

• Psychiatrists: Full authority. Telehealth prescribing allowed.
• PMHNPs: Must have 3+ years experience (4,600 hours) to practice independently as a ‘104 NP.’ Until then, need physician supervision. Must complete controlled-substance pharmacology course to prescribe Schedule II (RxAgent, 2025).
• Market: High demand, especially in metro areas (LA, SF, San Diego). Rural/Central Valley areas underserved. Competitive but large patient base.
• Watch out for: Mandatory e-prescribing (since 2022), strict privacy laws (CCPA).

Texas

• Psychiatrists: Full authority. No restrictions on telehealth ADHD prescribing (must use video, not just audio).
• PMHNPs: Cannot prescribe Schedule II stimulants to outpatients—only in hospital/hospice settings. You’ll need an MD to write Adderall prescriptions (RxAgent, 2025).
• Market: Severe psychiatrist shortage (1 per ~9,000 residents). Huge demand, especially in rural areas. High uninsured rate, but also growing Medicaid/private coverage (Healing Psychiatry Florida, 2026).
• Watch out for: NP restrictions make MDs essential. State scrutiny of controlled-substance prescribing is high post-scandals.

Florida

• Psychiatrists: Full authority. Florida explicitly allows telehealth prescribing of Schedule II for psychiatric disorders (Florida Statute 456.47).
• PMHNPs: Must work under psychiatrist protocol. Normally limited to 7-day Schedule II supplies, but psychiatric nurses treating mental health conditions are exempt and can prescribe 30-day supplies (Florida Statute 464.012).
• Market: Large, growing population. Psychiatrist shortage (1 per ~8,500 residents). High demand in South Florida and interior regions (Healing Psychiatry Florida, 2026).
• Watch out for: PMHNPs need psychiatrist collaboration. Mandatory PDMP checks. Active enforcement against inappropriate prescribing.

New York

• Psychiatrists: Full authority. No special telehealth restrictions.
• PMHNPs: Must complete 3,600 hours under physician supervision, then can practice independently with full prescribing authority (RxAgent, 2025).
• Market: Best psychiatrist-to-population ratio in the country (1:2,900), concentrated in NYC. Rural upstate areas still underserved. High insurance penetration (Healing Psychiatry Florida, 2026).
• Watch out for: Mandatory e-prescribing and PDMP checks for every controlled prescription. Competitive NYC market but strong demand statewide.

Pennsylvania

• Psychiatrists: Full authority. No state-specific telehealth barriers.
• PMHNPs: Must have collaborative agreement with physician. Can prescribe Schedule II, but only 72 hours’ worth initially, then 30-day supplies for ongoing therapy (RxAgent, 2025).
• Market: Moderate psychiatrist supply (1:4,586), concentrated in Philly/Pittsburgh. Rural central/northern PA underserved (Healing Psychiatry Florida, 2026).
• Watch out for: NP 72-hour initial limit creates workflow friction. Physician oversight required for NPs.

Illinois

• Psychiatrists: Full authority. Telehealth-friendly state with payment parity.
• PMHNPs: Can obtain Full Practice Authority after 4,000 hours + additional training. Until then, need collaborative agreement (RxAgent, 2025).
• Market: Moderate supply (1:5,800), concentrated in Chicago. Downstate Illinois has significant shortages (Healing Psychiatry Florida, 2026).
• Watch out for: Mandatory e-prescribing (since 2023). Document patient consent for telehealth.

Why Join a Telehealth Platform vs. Going Solo?

If you’re considering telehealth ADHD prescribing, you essentially have two paths: build your own practice or join an established platform.

Building Your Own Telehealth Practice: The Reality Check

What it actually costs to acquire patients yourself:

Let’s be clear about the economics here. Many articles online claim you can acquire psychiatric patients through DIY marketing for ‘$30-50 each’ or similar unrealistic figures. That’s nonsense.

In reality, acquiring a qualified psychiatric patient through your own marketing typically costs $200-500+ per patient when you account for:

• SEO: Takes 6-12 months of consistent investment (content, technical optimization, backlinks) before generating meaningful traffic. Most solo providers don’t have the expertise or patience.
• Google Ads: Mental health keywords run $15-40+ per click. Most clicks don’t convert to booked patients. Realistic cost per booked patient through PPC: $200-400+.
• Psychology Today/Zocdoc: Monthly subscription fees + per-booking charges. Zocdoc charges $35-100+ per booking, plus the monthly platform fee. Psychology Today is $30-100/month and you’re competing with hundreds of other providers on the same page.
• Failed campaigns and testing: Most ad campaigns require 3-6 months of optimization before they’re profitable. That’s wasted spend while you figure out what works.
• Staff time: Handling leads, qualifying patients, dealing with no-shows from cold leads—all hidden costs.

Total monthly investment for DIY marketing: Easily $3,000-5,000/month in ad spend, agency fees, and staff time, with no guaranteed ROI.

Why Platforms Like Klarity Make Economic Sense

Instead of gambling $3-5K/month on marketing with uncertain results, platforms like Klarity Health use a pay-per-appointment model:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

It’s a guaranteed ROI model: you pay a standard listing fee per new patient lead, but only when a qualified patient actually books with you. Compare that to spending $4,000/month on Google Ads hoping for a few appointments.

For providers just starting out, scaling up, or who value predictable patient flow without the marketing headache, platforms remove the risk entirely.

What to Look For in a Platform

If you’re evaluating platforms, ask:

• What’s the patient quality like? Are they pre-screened for insurance, location, and appropriateness?
• What’s your pricing model? Flat fee per appointment? Percentage of revenue? Subscription + per-booking?
• Do you provide malpractice insurance or require I carry my own?
• What states do you operate in, and will you help me get licensed if I need additional state licenses?
• For PMHNPs: Do you arrange collaborating physicians in restricted states, or am I responsible for finding my own?
• How do you handle PDMP checks, e-prescribing, and compliance? (Should be built into the platform.)
• What’s the patient volume like? Can I expect a full schedule, or will I be fighting for appointments?

Key Takeaways: What You Need to Know Right Now

1. Yes, psychiatrists can prescribe ADHD meds via telehealth in 2026—but federal rules are extended only through the end of 2025. Have a contingency plan in case the Ryan Haight in-person requirement returns.

2. PMHNPs’ ability to prescribe stimulants varies wildly by state. In Texas, you can’t prescribe them to outpatients at all. In New York or Illinois, you can practice independently after meeting experience requirements.

3. Standard of care still applies in telehealth. Thorough evaluations, informed consent, PDMP checks, appropriate follow-up—no shortcuts.

4. Reimbursement is solid. Telehealth payment parity is nearly universal for mental health. Psychiatrists typically earn $90-200+ per visit depending on code and payer.

5. Demand is high and not slowing down. ADHD diagnosis rates surged during the pandemic and have stayed elevated. Patients want convenient, virtual care—and waitlists for traditional psychiatry remain long.

6. Economics favor platforms over DIY. Building your own patient base costs $3-5K/month with uncertain results. Platforms like Klarity offer pre-qualified patients with a pay-per-appointment model—guaranteed ROI vs. gambling on marketing.

7. Medication shortages and scrutiny are real. Be prepared to navigate supply issues and demonstrate high-quality care to avoid regulatory trouble.

If you’re a psychiatrist or PMHNP looking to leverage telehealth for ADHD care, the opportunity is massive—but so is the need for compliance, quality, and smart practice economics. Do it right, and you can build a thriving, efficient practice. Cut corners, and you’ll find yourself in regulatory crosshairs.

Want to skip the marketing headaches and start seeing pre-qualified ADHD patients via telehealth? Explore joining Klarity Health’s provider network—no upfront costs, no wasted ad spend, just patients ready to see you.

Frequently Asked Questions

Can I prescribe ADHD medications via telehealth without ever seeing the patient in person?

As of early 2026, yes—federal COVID-era flexibilities allow psychiatrists to prescribe Schedule II stimulants (Adderall, Ritalin, etc.) via telehealth without an initial in-person exam. This has been extended through the end of 2025 (Axios, Nov 2024). However, this could change in 2026 if the waiver expires and the Ryan Haight Act’s in-person requirement returns. Check DEA guidance for updates.

Do PMHNPs have the same prescribing authority as psychiatrists for ADHD meds?

No—it depends entirely on your state. Psychiatrists (MD/DO) have full prescribing authority everywhere. PMHNPs’ authority varies: in states like New York and Illinois, experienced PMHNPs can prescribe stimulants independently. In Texas, PMHNPs cannot prescribe Schedule II stimulants to outpatients at all. In Florida and Pennsylvania, PMHNPs need physician collaboration and face additional limits (RxAgent, 2025).

Do I need to check the PDMP every time I prescribe a stimulant?

It depends on your state. New York requires PDMP checks for every controlled substance prescription (Healing Psychiatry Florida, 2026). Many other states require checking at least before the initial prescription and periodically (e.g., every 90 days) for ongoing therapy. Even if your state doesn’t mandate it, checking the PDMP is best practice to identify potential red flags (overlapping prescriptions, doctor shopping).

Can I prescribe ADHD meds via audio-only (phone) visits, or does it have to be video?

Federal law during the COVID waiver period allowed audio-only for some controlled substances, but many states require live video for controlled-substance prescribing. For example, Texas prohibits prescribing controlled substances via audio-only telehealth except in very limited situations (CCHP, 2026). To be safe, use live video for ADHD medication management—it also meets the higher standard of care.

How much can I realistically earn doing telehealth ADHD medication management?

If you’re a psychiatrist billing Medicare/commercial insurance, expect ~$89-95 for a 15-minute med check (99213) or ~$125-136 for a 25-minute visit (99214) (Therathink, 2026). Private insurance often pays more. If you see four patients per hour at $100+ average per visit, that’s $400+/hour gross—with minimal overhead since you’re working from home. Medicaid pays less (~$40-65/visit), but volume is often higher.

What happens if my patient’s Adderall is on backorder due to the shortage?

This is a real issue. Adderall and other stimulants have been periodically backordered since late 2022 (Axios, 2024). Options: work with the patient to find a pharmacy with stock, switch to an alternative stimulant (e.g., methylphenidate if they were on amphetamine, or vice versa), consider non-stimulants (atomoxetine, viloxazine, bupropion), or adjust the dose/formulation. Document the shortage and your clinical rationale for any changes.

Do I need malpractice insurance that specifically covers telehealth?

Yes. Make sure your malpractice policy covers telehealth services and prescribing controlled substances via telemedicine. Some older policies exclude telehealth or have geographic restrictions. If you’re practicing across multiple states, verify your coverage extends to all states where you’re licensed. Many telehealth platforms provide or require specific coverage.

Can I treat ADHD patients across state lines via telehealth?

Only if you hold an active medical license in the state where the patient is physically located at the time of the visit. You need a separate license for each state (though some states participate in interstate compacts to streamline this). You also need to follow that state’s prescribing rules, PDMP requirements, and telehealth regulations. Treating a patient in a state where you’re not licensed is illegal and puts your license at risk.

What’s the difference between joining a telehealth platform vs. building my own practice?

DIY practice: You control everything, but you’re responsible for marketing (SEO, ads, directories), patient acquisition (typically costs $200-500+ per patient when done right), credentialing with insurers, telehealth infrastructure, and compliance. Realistic monthly marketing spend: $3,000-5,000 with uncertain ROI.

Platform (like Klarity): Pre-qualified patients matched to your availability, no upfront marketing costs, pay-per-appointment model (only pay when you see patients), built-in compliance and telehealth tech, often handles insurance billing. Trade-off: you pay a listing fee per patient or percentage of revenue, and you’re working within the platform’s ecosystem. For most providers, especially those starting out or scaling, platforms offer guaranteed patient flow with predictable economics.

Citations and Sources

The following sources were used to compile this guide. Each has been verified for accuracy and currency as of February 2026:

1. Axios – ‘COVID-era telehealth prescribing extended again’ (Nov 18, 2024) – Federal DEA/HHS extension of telehealth controlled-substance flexibilities through end of 2025. Link

2. Axios – ‘Telehealth prescribing mess could reach Congress’ (Sept 18, 2024) – Analysis of impending expiration of pandemic-era telehealth rules and policy debate. Link

3. Associated Press – ‘More adults sought help for ADHD during pandemic’ (Jan 10, 2024) – Data on surge in ADHD prescriptions during COVID, citing JAMA Psychiatry study. Link

4. Florida Senate – Florida Statute §456.47 (Telehealth) – Official state law explicitly allowing telehealth prescribing of Schedule II controlled substances for psychiatric disorders. Link

5. Florida Legislature – Florida Statute §464.012 (APRN Prescribing) – Official state law detailing NP prescribing limits and psychiatric nurse exception to 7-day Schedule II limit. [Link](https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the